Pfizer asks U.S. regulators for emergency COVID-19 vaccine use  CTV NewsView Full coverage on Google News
Trump accused U.S. drugmaker Pfizer of waiting to announce the success of their Phase 3 vaccine trial until the day after the presidential election in order to avoid helping him.Trump accused U.S. drugmaker Pfizer of waiting to announce the success of their Phase 3 vaccine trial until the day after the presidential election in order to avoid helping him.

Trump turns on Pfizer over vaccine timing

Pfizer said Friday it is asking U.S. regulators to allow emergency use of its COVID-19 vaccine, starting the clock on a process that could bring limited first shots as early as next month and eventually an end to the pandemic — but not until after a long, hard winter.Pfizer said Friday it is asking U.S. regulators to allow emergency use of its COVID-19 vaccine, starting the clock on a process that could bring limited first shots as early as next month and eventually an end to the pandemic — but not until after a long, hard winter.

Pfizer applied to Health Canada for approval of the vaccine on Oct. 9, according to the department's website and has been subject to a 'rolling' review since.Pfizer applied to Health Canada for approval of the vaccine on Oct. 9, according to the department's website and has been subject to a 'rolling' review since.

Pfizer files for emergency use of coronavirus vaccine in U.S. — what about in Canada? - National | Globalnews.ca

Emergency Use Authorization could pave the way for a rapid rollout of their coronavirus vaccine.Emergency Use Authorization could pave the way for a rapid rollout of their coronavirus vaccine.

Why Pfizer and BioNTech Stocks Rose Today | The Motley Fool

All we really want for Christmas is a COVID vaccine.

EDITORIAL: A very merry shot in the arm | Toronto Sun

EDITORIAL: A very merry shot in the arm | Toronto Sun

If we get mass rollout and uptake of vaccines, we can be cautiously optimisticIf we get mass rollout and uptake of vaccines, we can be cautiously optimistic

Will Covid-19 vaccines pave path back to normality?

On this, the week marking the anniversary of the first appearance in Hubei of SARS-CoV-2 in 2019, the biggest news is that there is good news at all. In an annus horibilis, we celebrate the breaks we get. On this, the week marking the anniversary of the first appearance in Hubei of SARS-CoV-2 in 2019, the biggest news is that there is good news at all. In an annus horibilis, we celebrate the breaks we get.

Chasing waterfalls | Philstar.com

The application to the U.S. Food and Drug Administration (FDA) comes just days after Pfizer and German partner BioNTech SE <22UAy.DE> <BNTX.O> reported final trial results that showed the vaccine was 95% effective in preventing COVID-19 with no major safety concerns. Pfizer Chief Executive Officer Albert Bourla confirmed the application had been made in a video posted on the company's website on Friday afternoon.The application to the U.S. Food and Drug Administration (FDA) comes just days after Pfizer and German partner BioNTech SE <22UAy.DE> <BNTX.O> reported final trial results that showed the vaccine was 95% effective in preventing COVID-19 with no major safety concerns. Pfizer Chief Executive Officer Albert Bourla confirmed the application had been made in a video posted on the company's website on Friday afternoon.

Pfizer files COVID-19 vaccine application to U.S. FDA

There are currently 11 COVID vaccines in large-scale phase three trials. Here is everything you need to know about them.There are currently 11 COVID vaccines in large-scale phase three trials. Here is everything you need to know about them.

The 11 vaccines closest to be being ready for the public

Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Pfizer and its German partner, BioNTech, are asking U.S. regulators to allow emergency use of its COVID-19 vaccine on Friday. Pfizer and its German partner, BioNTech, are asking U.S. regulators to allow emergency use of its COVID-19 vaccine on Friday. 

Pfizer, BioNTech apply for emergency approval in U.S. for COVID vaccine Friday

Bloomberg - Are you a robot?

Employers can and should play a central role in getting Americans vaccinated.Employers can and should play a central role in getting Americans vaccinated.

How Employers Should Prepare For The Covid-19 Vaccine

Pfizer and Moderna are seeking FDA approval for their vaccine candidates, though some questions remain.Pfizer and Moderna are seeking FDA approval for their vaccine candidates, though some questions remain.

Why the Pfizer and Moderna coronavirus vaccines seem to work better than expected

LONDON, Nov 20 ― A leading Covid-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said yesterday as it released its phase 2 trial results. The vaccine, developed by the University of Oxford and AstraZeneca, produced fewer side...LONDON, Nov 20 ― A leading Covid-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said yesterday as it released its phase 2 trial results. The vaccine, developed by the University of Oxford and AstraZeneca, produced fewer side...

Oxford Covid-19 vaccine safe for older adults, results show | Life | Malay Mail

US News: WASHINGTON: US biotech giant Pfizer and German partner BioNTech sought approval Friday to roll out their coronavirus vaccine early, a first step towar.US News: WASHINGTON: US biotech giant Pfizer and German partner BioNTech sought approval Friday to roll out their coronavirus vaccine early, a first step towar.

Covid-19: Pfizer/BioNTech seek first vaccine approval in US - Times of India

Pfizer / BioNTech’s and Moderna’s vaccines both require two doses, which is common for many vaccines. Multiple doses gives the immune system the opportunity to produce a specific and effective response.Two doses will help ensure the most effective immune response

The first COVID-19 vaccines will likely require two shots - The Verge

It’s been a busy month for coronavirus vaccine news. In the past few weeks, we’ve seen announcements of interim phase 3 trial results, final phase 3 trial results, an FDA application, and phase 2 results. By my count, that’s five news events about three vaccines. It’s a bit confusing. It’s been a busy month for coronavirus vaccine news. In the past few weeks, we’ve seen announcements of interim phase 3 trial results, final phase 3 trial results, an FDA application, and phase 2 results. By my count, that’s five news events about three vaccines. It’s a bit confusing.

Your Field Guide to the Four Potential COVID-19 Vaccines

By Hari Kumar The race for a vaccine against Covid-19 is entering the home stretch and reports indicate one or more companies will soon get the go-ahead to begin mass production. Governments across the world have promised their citizens speedy access but the task facing authorities in transporting, storing and administering the doses is enormous. […]

Now the hard part: Why getting Covid vaccines to billions worldwide may take longer than hoped | Hong Kong Free Press HKFP

Pfizer Reveals Their Coronavirus Vaccine Is 95% Effective After Completing Third Study Trial A new report from Pfizer has come out of their coronavirus vaccine trials about the success rate of the vaccine they have been developing to help eradicate the pandemic.…Read more here...

Pfizer Reveals Their Coronavirus Vaccine Is 95% Effective After Completing Third Study Trial | Coronavirus, health : Just Jared

Covid-19 vaccine: the next stepsCovid-19 vaccine: the next steps

Covid-19 vaccine: the next steps - RFI

Pfizer Inc. undefined and BioNTech undefined on Friday submitted an application for an emergency use authorization for their trial COVID-19 vaccine...Pfizer Inc. undefined and BioNTech undefined on Friday submitted an application for an emergency use authorization for their trial COVID-19 vaccine...

Pfizer, BioNTech make it official: COVID-19 vaccine EUA submitted - MarketWatch

University of Oxford scientists expect to report results from the late-stage trials of their COVID-19 vaccine by Christmas.University of Oxford scientists expect to report results from the late-stage trials of their COVID-19 vaccine by Christmas.

Oxford scientists expect COVID-19 vaccine data by Christmas | CTV News

AstraZeneca and Oxford have published the full coronavirus vaccine study detailing the strong immune response seen in older adults injected with their experimental drug in The Lancet. The COVID-19 vaccine is safe for the elderly and induces the desired immune response against the new virus.AstraZeneca and Oxford have published the full coronavirus vaccine study detailing the strong immune response seen in older adults injected with their experimental drug in The Lancet. The COVID-19 …

A third coronavirus vaccine might deliver results by Christmas – BGR

The president accused drugmaker Pfizer of waiting to announce the success of its phase III vaccine trial until the day after the Nov. 3 election in order to avoid helping him.The president accused drugmaker Pfizer of waiting to announce the success of its phase III vaccine trial until the day after the Nov. 3 election in order to avoid helping him.

TITLE: Trump: Pfizer and other drug companies delayed vaccine information deliberately

Scientists at the University of Oxford say their experimental COVID-19 vaccine shows a strong immune response among older people. The early results raise hopes that the vaccine can protect the people most at risk of getting severely ill from the new coronavirus.Scientists at the University of Oxford say their experimental COVID-19 vaccine shows a strong immune response among older people. The early results raise hopes that the vaccine can protect the people most at risk of getting severely ill from the new coronavirus.

Good News on Oxford’s COVID-19 Vaccine

Pfizer announced it applied for emergency authorization use for its vaccine candidate on Friday.Pfizer announced it applied for emergency authorization use for its vaccine candidate on Friday.

Catch up on the most important updates from this week.Catch up on the most important updates from this week.

Pfizer Seeks Vaccine Approval, the CDC Urges Restraint, and More Coronavirus News | WIRED

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

Recon: UK asks MHRA to review Pfizer COVID vaccine; Novartis signs deal for Mesoblast cell therapy | RAPS

This would likely be the first vaccine to reach the public in the U.S. What exactly happens next, and how soon can anyone expect to have access?This would likely be the first vaccine to reach the public in the U.S. What exactly happens next, and how soon can anyone expect to have access?

Pfizer Just Filed for Emergency Approval of Its Covid-19 Vaccine. What's Next?

Prime Minister Justin Trudeau warned Canadians that despite promising coronavirus vaccine developments, 'we are still facing many more months' of COVID-19 safety measures.Prime Minister Justin Trudeau warned Canadians that despite promising coronavirus vaccine developments, 'we are still facing many more months' of COVID-19 safety measures.

Trudeau cautions against ‘preliminary’ coronavirus vaccine talk | Globalnews.ca

What does emergency use for a COVID-19 vaccine mean? | 2020/11/20What does emergency use for a COVID-19 vaccine mean?

What does emergency use for a COVID-19 vaccine mean? | Taiwan News | 2020/11/20

American pharmaceutical company Pfizer is seeking approval for the emergency use of its coronavirus vaccine in the US. Early results show the vaccine appears 95 per cent effective at preventing mild to severe cases of COVID-19. The company says it should qualify for emergency use authorisation before final testing is fully complete. It's already started "rolling" applications in Europe and the UK. Meanwhile, US officials have warned Americans not to travel ahead of Thanksgiving. A resurgence of COVID-19 cases across the country has forced some states into lockdown, closing businesses and schools.American pharmaceutical company Pfizer is seeking approval for the emergency use of its coronavirus vaccine in the US. Early results show the vaccine appears 95 per cent effective at preventing mild to severe cases of COVID-19. The company says it should qualify for emergency use authorisation before final testing is fully complete. It's already started "rolling" applications in Europe and the UK. Meanwhile, US officials have warned Americans not to travel ahead of Thanksgiving. A resurgence of COVID-19 cases across the country has forced some states into lockdown, closing businesses and schools.

Very encouraging results from the Oxford Vaccine trialNovember turned out to be the month of good Covid-19 vaccine news. After the promising interim results of the Pfizer and Moderna Phase 3 trials, the result

Oxford Vaccine Safe And Effective In Older Adults As Well, Phase 2 Data Shows | IFLScience

For a country like India, with a population of 135 crores, where the number of new COVID-19 cases is decreasing, but the situation is still not favourable.  For a country like India, with a population of 135 crores, where the number of new COVID-19 cases is decreasing, but the situation is still not favourable.  

DNA Exclusive: Lack of commitment and systemic apathy increased dangers of COVID-19 pandemic | India News | Zee News

These are the top stories written by Business Insider's healthcare team for the week ending November 20.These are the top stories written by Business Insider's healthcare team for the week ending November 20.

Business Insider's biggest healthcare stories week ending November 20 - Business Insider

Researchers said they expect to release their late-stage trial results by Christmas. This would follow rival drugmakers releasing theirs earlier this month.Researchers said they expect to release their late-stage trial results by Christmas. This would follow rival drugmakers releasing theirs earlier this month.

AstraZeneca COVID-19 Vaccine Data Shows Promise In Elderly | HuffPost

Academics hail good news for immunisation programmes after Oxford study shows those who recover are protected for at least half a yearAcademics hail good news for immunisation programmes after Oxford study shows those who recover are protected for at least half a year

Covid-19 patients ‘highly unlikely’ to contract illness again for at least six months say scientists

The ChAdOx1 nCoV-19 vaccine is safe and provokes a good immune response in healthy older adults, results from Phase 2 of the study reveal.The ChAdOx1 nCoV-19 vaccine is safe and provokes a good immune response in healthy older adults, results from Phase 2 of the study reveal.

Oxford Covid-19 vaccine shown to be safe in older adults | Health24

Pfizer and Biontech are filing for an Emergency Use Authorization from the FDA for their vaccine. So when it's finally available, when do we all get it? We know that's one of your biggest questions. It's ours too. Here's the good news, local leaders have a plan to roll it out. The vaccine will first be sent to what the state is calling pre-positioning sites.Pfizer and Biontech are filing for an Emergency Use Authorization from the FDA for their vaccine. So when it's finally available, when do we all get it? We know that's one of your biggest questions. It's ours too. Here's the good news, local leaders have a plan to roll it out. The vaccine will first be sent to what the state is calling pre-positioning sites.

Once approved, vaccine will first arrive at 16 pre-positioned sites across Texas | WOAI

Once approved, vaccine will first arrive at 16 pre-positioned sites across Texas

Listen back to Ryan Seacrest’s chat with a Pzifer vaccine trial volunteer who received both doses:Listen back to Ryan Seacrest’s chat with a Pzifer vaccine trial volunteer who received both doses:

A government map showing the number of COVID-19 infections per capita on a county level for last week shows just how widespread COVID-19 has become across the United States.A government map showing the number of COVID-19 infections per capita on a county level for last week shows just how widespread COVID-19 has become across the United States.

COVID-19 US: Red wave map shows how widespread infection is | Daily Mail Online